MedTrace Logo

Mindfulness Training for First Responders

NCT06582927 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-05-15

No results posted yet for this study

Summary

The present study evaluates the efficacy of Mindfulness-Based Attention Training on measures targeting cognitive abilities and emotional well-being in first responders.

Conditions

  • Burnout

Interventions

BEHAVIORAL

Mindfulness-Based Attention Training (MBAT)

MBAT is an evidence-based 8-hour mindfulness program that comprises 4 central topics and associated practices. The concentration topic introduces participants to mindfulness "basics," including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others. The course content and materials in the present study will entail the foundational MBAT curriculum and other related content delivered virtually over Zoom but will consist of 8, 1-hour sessions delivered across 8 consecutive weeks.

Sponsors & Collaborators

  • Unlikely Collaborators Inc.

    collaborator UNKNOWN

  • University of Miami

    lead OTHER

Principal Investigators

  • Amishi Jha, PhD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-22
Primary Completion
2026-04-10
Completion
2026-04-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06582927 on ClinicalTrials.gov